Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biocompatibles developed innovative biopolymer-based medical devices and controlled-release drug delivery systems. Its main commercial focus was on embolization therapies using compressible PVA microspheres and proprietary polymer technologies for targeted cancer treatment. The company also had a significant contact lens business until its sale in 2002. It was acquired by BTG plc in 2010, which itself was acquired by Boston Scientific in 2019. Its core technologies are now part of Boston Scientific's interventional oncology portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biocompatibles.